Clinical and surgical management of pheochromocytomas and paragangliomas

Main Article Content

Valeria de Miguel
Paula Cuffaro
Juan Medici
Demetrio Cavadas

Abstract

Pheochromocytomas and paragangliomas are rare neuroendocrine tumors with different clinical manifestation associated with high morbidity and mortality. Recognize signs and symptoms is the first step in diagnosis. Urinary fractionated metanephrines have an excellent specificity and sensitivity. Computed Tomography (CT) is the first-choice imaging modality for location. F18-DG positron tomography (PET)/CT scanning is the functional modality of choice for metastatic disease. Surgery is the only curative treatment. Minimally invasive adrenalectomy is the surgical approach for most adrenal pheochromocytomas. Perioperative alpha and beta blockade for 7 to 14 days normalize blood pressure and prevent perioperative cardiovascular complications. Is recognize that at least one-third of the patients have disease-causing germline mutations. Genetic testing must be orientated to syndromic features, presentation, localization and biochemical profile of these tumors. Multidisciplinary teams at centers with appropriate expertise are recommended to ensure a favorable outcome

Downloads

##plugins.themes.bootstrap3.displayStats.noStats##
Published: 2015-09-30
Keywords:
pheochromocytoma, paraganglioma, neuroendocrina tumors, hypertension, incidentaloma, catecholamines, metanephrines, adrenalectomy, malignancy, genetics

Article Details

Section

Review

How to Cite

1.
de Miguel V, Cuffaro P, Medici J, Cavadas D. Clinical and surgical management of pheochromocytomas and paragangliomas. Rev Hosp Ital B.Aires [Internet]. 2015 Sep. 30 [cited 2026 Jul. 31];35(3):76-85. Available from: https://ojs.hospitalitaliano.org.ar/index.php/revistahi/article/view/710

References

Pacak K, JDR. Pheochromocytoma and Paraganglioma [Internet]. Available from: http://www.endotext.org/chapter/pheochromocytoma

Kirmani S, Young WF. Hereditary Paraganglioma-Pheochromocytoma Syndromes. Seattle: University of Washington; 2014.

van Berkel A, Lenders JW, Timmers HJ. Diagnosis of endocrine disease: Biochemical diagnosis of phaeochromocytoma and paraganglioma. Eur J Endocrinol. 2014;170(3):R109-19.

Mantero F, Terzolo M, Arnaldi G, et al. A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metab. 2000;85(2):637-44.

Mannelli M, Lenders JW, Pacak K, et al. Subclinical phaeochromocytoma. Best Pract Res Clin Endocrinol Metab. 2012;26(4):507-15.

Motta-Ramirez GA, Remer EM, Herts BR, et al. Comparison of CT findings in symptomatic and incidentally discovered pheochromocytomas. AJR Am J Roentgenol. 2005;185(3):684-8.

Lenders JW, Duh QY, Eisenhofer G, et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(6):1915-42.

Fuxe K, Manger P, Genedani S, et al. The nigrostriatal DA pathway and Parkinson’s disease. J Neural Transm Suppl. 2006;(70):71-83.

Pacak K, Lenders JWM, Eisenhofer G. Pheochromocytoma Diagnosis, Localization, and Treatment. Malden, MA: Blackwell Publishing; 2007. (http://www.wiley.com/WileyCDA/Wiley Title/productCd-1405149507.html )

Young WF, NM K. Clinical presentation and diagnosis of pheochromocytoma. UpToDate. 2015. http://www.uptodate.com/contents/clinical-presentation-and-diagnosis-of-pheochromocytoma

Baid SK, Lai EW, Wesley RA, et al. Brief communication: radiographic contrast infusion and catecholamine release in patients with pheochromocytoma. Ann Intern Med. 2009;150(1):27-32. Erratum in: Ann Intern Med. 2009 Feb 17;150(4):292.

Taïeb D, Varoquaux A, Chen CC, et al. Current and future trends in the anatomical and functional imaging of head and neck paragangliomas. Semin Nucl Med. 2013;43(6):462-73.

Castinetti F, Kroiss A, Kumar R, et al. 15 YEARS OF PARAGANGLIOMA: Imaging and imaging-based treatment of pheochromocytoma and paraganglioma. Endocr Relat Cancer. 2015;22(4):T135-45

Pacak K. Preoperative management of the pheochromocytoma patient. J Clin Endocrinol Metab. 2007;92(11):4069-79.

Prejbisz A, Lenders JW, Eisenhofer G, et al. Cardiovascular manifestations of phaeochromocytoma. J Hypertens. 2011;29(11):2049-60.

Zuber SM, Kantorovich V, Pacak K. Hypertension in pheochromocytoma: characteristics and treatment. Endocrinol Metab Clin North Am. 2011;40(2):295-311, vii.

Lebuffe G, Dosseh ED, Tek G, et al. The effect of calcium channel blockers on outcome following the surgical treatment of phaeochromocytomas and paragangliomas. Anaesthesia. 2005;60(5):439-44

Most read articles by the same author(s)